Novo Holdings A/S bought $16.2M of MapLight Therapeutics (MPLT)
Executed Oct 28 2025, disclosed Oct 30 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 30 2025), the stock returned -18.9% (delay-adjusted); from the execution session (Oct 28 2025), -27.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
Novo Holdings A/S (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in AVLN. Across 1 priced purchase filing, the average 21-session return was -4.8% from execution and -10.0% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of AVLN (555,555 sh × $18.00, as filed), executed May 1.
Healthcare · MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→